Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net revenue:
Total net revenues	$ 2,187	$ 2,736
Cost of goods sold	1,162	1,149
Gross margin	1,025	1,587
Operating expenses:
Research and development	578	556
Depreciation and amortization	52	50
Selling, general and administrative	2,348	1,999
Total operating expenses	2,978	2,605
Loss from operations	(1,953)	(1,018)
Other (expense) income:
Interest expense	(7)	(13)
Interest income	2	3
Extinguishment of PPP loan		482
Other (expense) income, net	(9)	9
Total other (expense) income:	(14)	481
Net loss	(1,967)	(537)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(63)	(59)
Net loss attributable to Nephros, Inc. shareholders	$ (2,030)	$ (596)
Net loss per common share, basic and diluted	$ (0.20)	$ (0.06)
Weighted average common shares outstanding, basic and diluted	10,213,898	9,883,035
Comprehensive loss:
Other comprehensive loss, foreign currency translation adjustments	$ (3)	$ (6)
Comprehensive loss	(1,970)	(543)
Comprehensive loss attributable to noncontrolling interest	(63)	(59)
Comprehensive loss attributable to Nephros, Inc. shareholders	(2,033)	(602)
Product [Member]
Net revenue:
Total net revenues	2,177	2,712
Royalty And Other revenue [Member]
Net revenue:
Total net revenues	$ 10	$ 24